MedTrace Logo

Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation

NCT03381053 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2017-12-21

No results posted yet for this study

Summary

Evaluate the reliability of morphology standards for GIST pathologic type, staging and grading by retrospective analyzing clinical data; on this basis, establish a GIST standardized and individualized treatment mode to maximum benefit GIST patients, avoid under- and over-treatment

Conditions

  • Method of Differentiating Benignancy and Malignancy, Grading and Staging for GIST

Interventions

DRUG

Imatinib 400mg

The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.

Sponsors & Collaborators

  • Ruijin Hospital

    collaborator OTHER

  • Fudan University

    collaborator OTHER

  • Changhai Hospital

    collaborator OTHER

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • Huashan Hospital

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Hou Ying Yong, Doctor · Shanghai Zhongshan Hospital

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2020-07-01
Completion
2022-01-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03381053 on ClinicalTrials.gov